Global Forum on Biotechnology, OECD, Nov.12,2012
The Next Challenges in Biotechnology of Japan Mitsuru Miyata, The excutive leader writer, Nikkei Business Publications,Inc. 宮田 満
日経BP社
Outline Current status of BT and Pharma in Japan History :National Policy to promote BT Top down Policy does not go well now. The Next Challenges of BT in Japan For Last minutes, critical problems in Biotechnology in Japan
Expected market in 2010 on “National BT Strategy ” Medical
Foods
8.4 trillion yen
6.3 trillion yen
＊Pharmaceuticals ＊Medical devices
＊Functional Foods (3.2) ＊Others (3.1)
Total
25 Environment/Energy
4.2 trillion yen ＊Bio-process (3.6) ＊Biomass (0.2) ＊Bioremediation (0.4)
trillion yen
Tools/Informatics
5.3 trillion yen ＊Instruments/Reagents(3.1) ＊Bioinformatics (2.2)
25 trillion yen = 220 bil. dollars
21
Real Bio Market in Japan Over
( in M\ )
2.4Tyen in 2010
Pharma in Japan are failing down Patent expiration of Major Product
Emerging Technology Information Center、All Right
5
1150Byen in 2010, Import surplus of Therapeutics
Emerging Technology Information Center、All Right Reserved, Nikkeib Business
6
Lost decade of Japanese Biophartherapeutics
Emerging Technology Information Center、All Right
(山口ら、09年） 7
Reasons of the first failure in Biotechnology in Japan
Conservative culture Bad and Poor Science Policy Gap between industry and Academy Poor venture financing and activity Poor Public Acceptance especially to GMO
The New strategy for national growth by DPJ Dec.39,09
Av.3% GDP Growth until 2020 GDP 650 T Yen in 2020 (473T Yen,2009) Unemployment rate less than 4%
Emerging Technology Information Center、All Right Reserved, Nikkeib Business
9
Goal :Job Creation for Brain workers No one believes the policy in Japan Energy/Environment
Emerging Technology Information Center、All Right Reserved, Nikkeib Business
Health/Medical/Care
10
Research Institutes of Big Pharma. Disappeared in Japan
Emerging Technology Information Center、All Right Reserved, Nikkeib Business
11
But, Big Pharma may loose good opportunities of Bio Innovation in Japan
New type of biotechnological research based on Japanese culture ----Full Length cDNA Project
not enough money and human
resources for whole human genome analysis in Japan From 1997, focusing research on full length cDNA due to less than 1% of genome Now, We have about 30,000 cDNA Applying to Targeted Proteomics to find the function of genes and make them patentable.
Full Length cDNA Project leads to Innovation of iPS Cell
Full Length cDNA Project leads to Innovation of iPS Cell 20th Nov,2007 Human iPS Cell 2006, Murine iPS Cell Established 4Genes Introduced Oct3/4、Sox2、（cMyc）、Klf4 ,selected from cDNA Database
New type of biotechnological research based on Japanese culture
Personalized Medicine
Hap- map Program Genomic Cohort study From 2003, the national program collecting DNA and MR from 300,000 patients
GWAS can find genes with high risk of diseases
Disease Risk gene
50万個のSNPが並んでる 〔鎌谷、2008）
Poteligent CH Engneering Eradication fucose from IgG
Poteligeo Launched 29 May in 2012 Kyow Kirin antiCCR4 Mab with modified Sugar chains/ Adult T Cell Leukemia
Emerging Technology Information Center、All Right Reserved, Nikkeib Business
19
The only one commercial plant for recombinant hAlbumin Oct. 2007 operation Pichia based Fermentation plant
Emerging Technology Information Center、All Right Reserved, Nikkeib Business
20
New type of biotechnological research based on Japanese culture Bioelectronics/Nanobiology
Bio Computer
Super Computer “KEI” began operation in Sept. of 2012
Emerging Technology Information Center、All Right Reserved, Nikkeib Business
22
Molecular Dynamics Protein/Ligand Simulation with KEI Virtual Drug Discovery
3.5PFLOPSの京コンピュータ上で、 1.315PFLOPSの性能を達成 効率 37% 細胞混雑下でのタンパク質動態シミュレーション 1.8億原子、 カットオフ これまで行われたタンパ ク質の分子動力学シミュ レーションで最高の性能 ※本成果は、グランドチャレンジプロジェク ト「次世代生命体統合シミュレーション」の 一環であり、早期の成果創出の要求に基づき マシン割り当てに特別な配慮をいただいて実 現したものです。
23
New type of biotechnological research based on Japanese culture ----Functional Food Food for enhancing health , based on research of traditional dishes in Japan Our longevity is partly due to Japanese food More than 2000M$ for functional food market Modern Biotechnology is applied to study and to understand healthy element in food at molecular level
March 11th ,2011 East Japan Earthquake and Tsunami
Emerging Technology Information Center、All Right Reserved, Nikkeib Business
25
Big Money to RecoverTohoku area Some in Advanced Medicine Tohoku Medical Megabank 15.8Byen（2011）＋5.6Bye（2012） 3Generation Genome Cohort、150,000people Multi Omics Research Center Fukushima Drug Discovery Platform 25.8Bye for 10years from 2012 Multi Omics Research Center Fukushima Pref. Med. Examination 2Mpeople Emerging Technology Information Center、All Right Reserved, Nikkeib 26 Business Publications,Inc.2003
Multi Omics Research Center in Fukusima
Emerging Technology Information Center、All Right Reserved, Nikkeib 27 Business Publications,Inc.2003
Multi Omics Research Center will complete this month.in Fukushima
28 Emerging Technology Information Center、All Right Reserved, Nikkeib Business Publications,Inc.2003
We need risk money for emerging companies
Source: OECD 1999-2004, IVC Research Center 2004
Failure to Get Public Acceptance to GMO in last 2decades Almost everyone believe no GMO in Japan The largest importer of GMO on the globe is Japan Japanese travelers love to eat rPapaya in Hawaii nether in Japan
Emerging Technology Information Center、All Right Reserved, Nikkeib Business
30
Future of Japanese Bioindustry Hoping Bright Future By Continuous Scientific Innovation By Fusing BT,ICT, NT and ET By Combining Innovation , Precise Manufacturing and Design By Creating and Financing Smart Bioventure Companies BY Alliance with Global Talent and Brain
The Last Critical Question: Can we pay for Next Biotechnological Inovation? 10.0% of GDP for Healthcare 1000TYen National Debt The fastest aging society on the globe. The Final Option →VAT or DEAD/Debt
Austria France Italy Germany England
２０．０ １% ２０．６ １% ２０．０ １ % １６．０ １% １７．５%
Contact::
[email protected]
33
